研究者業績
基本情報
- 所属
- 藤田医科大学 医学部 医学科 先端光学診療学講座
- 学位
- 博士(医学）
- J-GLOBAL ID
- 200901011108502975
- researchmap会員ID
- 6000005568
患者さんの立場にたって、安全かつ最高の医療を提供できるよう努力します。
研究キーワード
8研究分野
1委員歴
28-
2024年2月 - 現在
-
2023年2月 - 現在
-
2022年9月 - 現在
受賞
4-
2022年10月
-
2019年10月
-
2015年10月
論文
270-
The Journal of dermatology 2024年9月30日 査読有り
-
JAMA 2024年7月22日 査読有りImportance The clinical effects of risankizumab (a monoclonal antibody that selectively targets the p19 subunit of IL-23) for the treatment of ulcerative colitis are unknown. Objective To evaluate the efficacy and safety of risankizumab when administered as an induction and a maintenance therapy for patients with ulcerative colitis. Design, Setting, and Participants Two phase 3 randomized clinical trials were conducted. The induction trial was conducted at 261 clinical centers (in 41 countries) and enrolled 977 patients from November 5, 2020, to August 4, 2022 (final follow-up on May 16, 2023). The maintenance trial was conducted at 238 clinical centers (in 37 countries) and enrolled 754 patients from August 28, 2018, to March 30, 2022 (final follow-up on April 11, 2023). Eligible patients had moderately to severely active ulcerative colitis; a history of intolerance or inadequate response to 1 or more conventional therapies, advanced therapies, or both types of therapies; and no prior exposure to risankizumab. Interventions For the induction trial, patients were randomized 2:1 to receive 1200 mg of risankizumab or placebo administered intravenously at weeks 0, 4, and 8. For the maintenance trial, patients with a clinical response (determined using the adapted Mayo score) after intravenous treatment with risankizumab were randomized 1:1:1 to receive subcutaneous treatment with 180 mg or 360 mg of risankizumab or placebo (no longer receiving risankizumab) every 8 weeks for 52 weeks. Main Outcomes and Measures The primary outcome was clinical remission (stool frequency score ≤1 and not greater than baseline, rectal bleeding score of 0, and endoscopic subscore ≤1 without friability) at week 12 for the induction trial and at week 52 for the maintenance trial. Results Among the 975 patients analyzed in the induction trial (aged 42.1 [SD, 13.8] years; 586/973 [60.1%] were male; and 677 [69.6%] were White), the clinical remission rates at week 12 were 132/650 (20.3%) for 1200 mg of risankizumab and 20/325 (6.2%) for placebo (adjusted between-group difference, 14.0% [95% CI, 10.0%-18.0%], P < .001). Among the 548 patients analyzed in the maintenance trial (aged 40.9 [SD, 14.0] years; 313 [57.1%] were male; and 407 [74.3%] were White), the clinical remission rates at week 52 were 72/179 (40.2%) for 180 mg of risankizumab, 70/186 (37.6%) for 360 mg of risankizumab, and 46/183 (25.1%) for placebo (adjusted between-group difference for 180 mg of risankizumab vs placebo, 16.3% [97.5% CI, 6.1%-26.6%], P < .001; adjusted between-group difference for 360 mg of risankizumab vs placebo, 14.2% [97.5% CI, 4.0%-24.5%], P = .002). No adverse event signals were detected in the treatment groups. Conclusion and Relevance Compared with placebo, risankizumab improved clinical remission rates in an induction trial and in a maintenance trial for patients with moderately to severely active ulcerative colitis. Further study is needed to identify benefits beyond the 52-week follow-up. Trial Registration ClinicalTrials.gov Identifiers: NCT03398148 and NCT03398135
-
Journal of gastrointestinal and liver diseases : JGLD 33(2) 164-169 2024年6月29日 査読有りBACKGROUND AND AIMS: Early gastric cancers (EGCs) after Helicobacter pylori (H. pylori) eradication often appear as reddish depressed lesions (RDLs); the same features are also appeared in benign stomachs after eradication. We compared clinic-pathological and endoscopic features of benign and neoplastic RDLs after H. pylori eradication. METHODS: 228 neoplastic RDLs after H. pylori eradication were studied. All lesions were divided into neoplastic RDLs (differentiated carcinoma or adenoma, n=114) and benign RDLs (n=114) according to the histology. Clinical and pathological characteristics were compared in neoplastic and benign groups. Endoscopic diagnostic yields using the white light (WL) endoscopy, chromoendoscopy (CE) using indigo carmine dye and the magnifying endoscopy with narrow-band imaging (ME-NBI) were also evaluated in relation to the pathological diagnosis. RESULTS: Size of neoplastic RDLs was larger than that of benign RDLs (p<0.01). Sensitivity, specificity and accuracy for predicting pathological types of RDLs was 70.1%, 52.6% and 61.4% for the WL, 65.8%, 63.1% and 65.4% for the CE, while the ME-NBI scored better with the 88.6%, 88.6%, 99.1% and 93.9% of sensitivity, specificity and accuracy. The accuracy of the ME-NBI was 99.9% (113/114) in the benign RDLs and 89.4% (101/114) for the neoplastic RDLs. Undiagnosed neoplastic RDLs using the ME-NBI were associated with more differentiated tumors such as adenoma and well-differentiated adenocarcinoma (tub1) and the presence of an unclear demarcation line. CONCLUSIONS: ME-NBI is useful to diagnose RDLs after H. pylori eradiation, while some of neoplastic lesions are difficult to diagnose using the ME-NBI.
-
Journal of gastroenterology 59(5) 376-388 2024年5月 査読有りBACKGROUND: The clinicopathological features and prognosis of primary small bowel adenocarcinoma (PSBA), excluding duodenal cancer, remain undetermined due to its rarity in Japan. METHODS: We analyzed 354 patients with 358 PSBAs, between January 2008 and December 2017, at 44 institutions affiliated with the Japanese Society for Cancer of the Colon and Rectum. RESULTS: The median age was 67 years (218 males, 61.6%). The average tumor size was 49.9 (7-100) mm. PSBA sites consisted of jejunum (66.2%) and ileum (30.4%). A total of 219 patients (61.9%) underwent diagnostic small bowel endoscopy, including single-balloon endoscopy, double-balloon endoscopy, and capsule endoscopy before treatment. Nineteen patients (5.4%) had Lynch syndrome, and 272 patients (76.8%) had symptoms at the initial diagnosis. The rates for stages 0, I, II, III, and IV were 5.4%, 2.5%, 27.1%, 26.0%, and 35.6%, respectively. The 5-year overall survival rates at each stage were 92.3%, 60.0%, 75.9%, 61.4%, and 25.5%, respectively, and the 5-year disease-specific survival (DSS) rates were 100%, 75.0%, 84.1%, 59.3%, and 25.6%, respectively. Patients with the PSBA located in the jejunum, with symptoms at the initial diagnosis or advanced clinical stage had a worse prognosis. However, multivariate analysis using Cox-hazard model revealed that clinical stage was the only significant predictor of DSS for patients with PSBA. CONCLUSIONS: Of the patients with PSBA, 76.8% had symptoms at the initial diagnosis, which were often detected at an advanced stage. Detection during the early stages of PSBA is important to ensure a good prognosis.
-
日本消化器病学会雑誌 121(臨増総会) A190-A190 2024年3月
MISC
1258-
HEPATO-GASTROENTEROLOGY 57(99-100) 487-492 2010年5月 査読有りBackground/Aims: Colorectal cancer (CRC) was first recognized as a complication of ulcerative colitis (UC) in 1925, and the increased risk has since been confirmed in a multitude of epidemiological studies. To our knowledge, however, all of these studies have been conducted in Western countries. The aim of this study was to identify the clinicopathological features of ulcerative colitis-related CRC in a consecutive series of patients at a single hospital in central Japan. Methodology: 314 (170 males, 144 females, mean age 30) consecutive patients diagnosed with ulcerative colitis were enrolled and investigated for the development of CRC. 240 patients had relapsing-remitting disease, 54 had chronic continuous disease, 16 had experienced one attack only, 2 had the acute fulminating type, and 2 were unknown. With regard to disease extension, 181 cases were of the pan-colitis type, 84 were left-sided colitis, and 42 were proctitis. Two patients (1%) had a family history of colorectal cancer and 45 (14%) were past or current smokers. Results: Colorectal cancer developed in seven patients (male to female ratio of 1:6), which was 2.2% of the total. Average age at the onset of ulcerative colitis was 28 years. Average age at the onset of cancer was 44 years, and average duration of UC at cancer onset was 192 months. Ulcerative colitis was of the pancolitis type in all cases. Three patients (43%) showed the relapse-remitting type and four (57%) the chronic continuing type. Three patients (43%) had a family history of cancer, in particular colorectal cancer in one patient (14%). None of the patients had a history of smoking. The histological type of cancer was well differentiated tubular adenocarcinoma in three patients (43%) and poorly differentiated adenocarcinoma in three patients (43%) each, and endocrine cell carcinoma in one (14%). Conclusions: In this group of Japanese patients, development of colorectal cancer was more likely to occur in patients with ulcerative colitis that was long-standing, and more extensive than left-sided colitis, particularly in those with a family history of colorectal cancer, inflammatory polyps, or dysplasia. CRCs in our patients with UC were often poorly differentiated and had a poor prognosis.
-
Journal of experimental & clinical cancer research : CR 29 36-36 2010年4月25日 査読有りBackground: Analysis of gene expression and gene mutation may add information to be different from ordinary pathological tissue diagnosis. Since samples obtained endoscopically are very small, it is desired that more sensitive technology is developed for gene analysis. We investigated whether gene expression and gene mutation analysis by newly developed ultra-sensitive three-dimensional (3D) microarray is possible using small amount samples from endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) specimens and pancreatic juices. Methods: Small amount samples from 17 EUS-FNA specimens and 16 pancreatic juices were obtained. After nucleic acid extraction, the samples were amplified with labeling and analyzed by the 3D microarray. Results: The analyzable rate with the microarray was 46% (6/13) in EUS-FNA specimens of RNAlater (R) storage, and RNA degradations were observed in all the samples of frozen storage. In pancreatic juices, the analyzable rate was 67% (4/6) in frozen storage samples and 20% (2/10) in RNAlater (R) storage. EUS-FNA specimens were classified into cancer and non-cancer by gene expression analysis and K-ras codon 12 mutations were also detected using the 3D microarray. Conclusions: Gene analysis from small amount samples obtained endoscopically was possible by newly developed 3D microarray technology. High quality RNA from EUS-FNA samples were obtained and remained in good condition only using RNA stabilizer. In contrast, high quality RNA from pancreatic juice samples were obtained only in frozen storage without RNA stabilizer.
-
GASTROINTESTINAL ENDOSCOPY 71(5) AB345-AB346 2010年4月
-
GASTROINTESTINAL ENDOSCOPY 71(5) AB275-AB275 2010年4月
-
GASTROINTESTINAL ENDOSCOPY 71(5) AB372-AB372 2010年4月
-
GASTROINTESTINAL ENDOSCOPY 71(5) AB294-AB294 2010年4月
-
GASTROINTESTINAL ENDOSCOPY 71(5) AB373-AB374 2010年4月
-
GASTROINTESTINAL ENDOSCOPY 71(5) AB279-AB279 2010年4月
-
GASTROINTESTINAL ENDOSCOPY 71(5) AB270-AB270 2010年4月
-
GASTROINTESTINAL ENDOSCOPY 71(5) AB181-AB182 2010年4月
-
超音波医学 37(Suppl.) S255-S255 2010年4月
-
Gastroenterological Endoscopy 52(Suppl.1) 800-800 2010年4月
-
Journal of gastroenterology 45(4) 468-9 2010年4月 査読有り
-
Journal of gastroenterology and hepatology 25(4) 712-8 2010年4月 査読有りBackground and Aim: Relationships between mucin phenotype and malignant potential in gastric cancers have attracted attention. We attempted to assess the possibility of obtaining phenotypic diagnoses by confocal endomicroscopy. Methods: Confocal images of target lesions were obtained in 29 of 40 patients with gastric cancer. Appearances of the brush border, goblet cells, and gastric foveolar epithelium were investigated with immunohistochemical staining using CD10, MUC2, and human gastric mucin to evaluate phenotypic expression in gastric carcinomas. Confocal images were compared with immunohistochemical findings for goblet cells and brush borders. Results: Both the endoscopists and the pathologist obtained high accuracy rates for differential diagnosis. Sensitivity and specificity for goblet cells were 85.7% and 92.3% (Endoscopist A), and 85.7% and 88.5% (Endoscopist B). The kappa-value for correspondence between two endoscopists for the diagnosis of goblet cells in confocal images was 0.73. Sensitivity and specificity for the brush border were 93.8% and 91.7% (Endoscopist A), and 81.3% and 91.7% (Endoscopist B). The kappa-value for correspondence between two endoscopists for diagnosis of the brush border in confocal images was 0.79. Intestinal phenotypic gastric cancers show a brush border, goblet cells, or both. Sensitivity and specificity for the intestinal phenotype in confocal endomicroscopy were 90.9% and 77.8% (Endoscopist A), and 86.4% and 83.3% (Endoscopist B). Conclusion: The confocal endomicroscopic diagnosis of the mucin phenotype in gastric cancers was limited to intestinal and mixed phenotypes, but may be useful for the diagnosis of mucin phenotype and differential diagnosis.
-
消化器と免疫 (46) 180-183 2010年3月酢酸は、腸管細菌叢が産生する短鎖脂肪酸の多くの部分を占め、炎症性腸疾患ではその産生量の減少が報告されている。我々はマウスの炎症疾患モデルに対して酢酸と同様の効果がある酢酸Naが抗炎症効果について報告してきた。今回、潰瘍性大腸炎患者4例およびクローン病患者1例に対して酢酸Na注腸を4週間施行した。全例で副作用なく施行でき、潰瘍性大腸炎患者4例中2例、クローン病患者1例で内視鏡所見や臨床症状の改善がみられた。(著者抄録)
-
THROMBOSIS and Circulation 18(3) 46(200)-49(203) 2010年＜§論文のポイント＞[1]カプセル内視鏡やバルーン内視鏡の開発は小腸疾患に大きな変化をもたらした。[2]アスピリンは上部消化管だけでなく小腸粘膜障害を高率に引き起こす。[3]予防や治療に関してPG製剤、レバミピドなどの有用性が報告されているが、明らかなevidenceはない。(著者抄録)
-
消化器内科 50(2) 180-183 2010年術前に進展範囲診断目的で内視鏡的逆行性胆管造影(ERC)の手技を用いた経乳頭的胆管生検を施行し、最終的に胆管癌と診断された48例(男33例・女15例・平均67.7歳)について報告した。生検目的のERCは53回施行し、48例中14例で造影像よりも広範な癌の進展が証明された。肉眼的形態分類別にみると、結節型19例中9例、乳頭型13例中4例、平坦型16例中1例であった。術後膵炎は53回の検査後7回で認めたが、全例軽度で保存的に改善した。術後胆管炎は4回で認め、術前に内瘻によるドレナージが留置されていた症例に多かった。以上、経乳頭的胆管生検は胆管癌の術前診断として有用であると考えられた。
-
消化器の臨床 13(2) 184-189 2010年カプセル内視鏡が臨床導入され、非ステロイド系抗炎症薬(NSAID)による小腸粘膜傷害の存在が顕在化するようになってきた。我々は2004年よりカプセル内視鏡による小腸疾患の臨床研究に着手し、NSAID小腸粘膜傷害を比較的容易に観察できることを報告してきた。また、NSAID小腸粘膜傷害の予防に関する研究が必要と考えていた。そこで、ボランティアを用いレバミピドによるNSAID誘発小腸傷害予防試験を実施し、その有用性を確認した。(著者抄録)
-
胆と膵 31(10) 1245-1248 2010年膵癌は消化器癌のみならず、全ての悪性腫瘍の中で最も予後不良な腫瘍の一つである。現在、切除不能局所進行膵癌に対して化学放射線療法が有効であると考えられているが、十分な治療効果が得られているとは言い難く、新しい治療法の開発が求められている。そこで、われわれのチームでは、切除不能局所進行膵癌患者5例に対する一次治療として、標準化学療法剤であるゲムシタビン(GEM)と樹状細胞(DC)のEUSガイド下腫瘍内局所投与、およびCD3-LAK(Lymphokine-activated killer cells)静脈内投与を併用した臨床試験を実施した。その結果、グレード3以上の有害事象は認められず、PR(partial response)1例、6ヵ月間以上のSD(stable disease)2例、PD(progressive disease)2例と良好な結果が得られため、本稿では試験の方法論および結果について紹介する。(著者抄録)
-
胃と腸 45(13) 2079-2084 2010年Peutz-Jeghers症候群の小腸ポリープは腸重積,出血,腹痛の原因となるが,近年のカプセル内視鏡(VCE),ダブルバルーン内視鏡(DBE)の開発でその診断・治療は容易となった.小腸ポリープ数の比較試験では小腸X線と比較し,VCE,DBEの検出能は優れており,さらにVCEはDBEに比し全小腸観察率が高かった.DBE下小腸ポリープ摘除は有効かつ低侵襲であった.回収したポリープの病理学的検索では20mm以下のポリープの腺腫合併率は1%,20mmを超えるポリープの腺腫・腺癌の合併率は27%と有意差があった.小腸ポリープの増殖能を規定する因子は小腸,大腸ポリープ数であったことから,ポリープ摘除後のフォローアップは小腸,大腸ポリープ数を勘案して半年〜4年ごとにカプセル内視鏡で行うのがよいと思われた.(著者抄録)
-
Gastroenterological Endoscopy 51(11) 2866-2876 2009年11月原因不明の消化管出血(OGIB)例におけるカプセル内視鏡(VCE)の診断的意義について検討した。対象は2004年11月〜2008年2月までにVCE、ダブルバルーン内視鏡(DBE)の順で精査を行ったOGIB例116例(男性70例、女性46例、平均年齢62.2歳)で、VCEの診断および所見をDBEや生検などの組織診断による最終診断と比較した。その結果、VCEの有所見率は73例(62.9%)であったが、VCEでOGIBの診断を得たのは20例(17.2%、内訳はangiodysplasia:17例、回腸癌、鉤虫症、動静脈奇形:各1例)であり、最終診断と一致したのは13例(11.2%、内訳はangiodysplasia:10例、回腸癌、鉤虫症、動静脈奇形:各1例)と低率であった。尚、VCEの感度は76.7%、特異度は74.2%で、陽性的中率は87.5%、陰性的中率は57.5%、正診率は76.0%であった。以上、VCEではOGIBと最終診断を得るのは少ないが、最終診断への有効な情報源として有用と考えられた。
-
Journal of gastroenterology and hepatology 24(11) 1733-9 2009年11月 査読有りBackground and Aim: Confocal endomicroscopy is ultra-high-magnification endoscopy with histological observation during ongoing endoscopy. We planned a pilot study of the diagnosis of the depth of esophageal cancer using confocal endomicroscopy for treatment strategies. Methods: Patients had 14 superficial esophageal cancers and one dysplasia. The depth of neoplasms in 15 lesions was confirmed by endoscopic mucosal resection or surgery. We examined the rate of delineation and compared results of confocal imaging with histological findings. We classified two cellular and three microvascular patterns on confocal endomicroscopic images: CP-N for normal squamous mucosa and CP-Ca for cancerous lesion; VP-type A for normal squamous mucosa; VP-type B for T1a-EP and T1a-LPM cancers; and VP-type C for T1a-MM or a more invasive cancer pattern. We measured diameters of microvessels for the three patterns of confocal endomicroscopic images and histological specimens. Results: The rate of delineation was 73.3% (11/15) for esophageal cancer. The results of confocal imaging coincided well with microvessel distribution on horizontal histology. Two endoscopists blindly diagnosed the two types by cellular pattern and the three types by vascular pattern: their overall accuracies were 96% and 89% for the cellular pattern and 85% and 85% for the vascular pattern, respectively. The k value of the cellular pattern and the vascular pattern diagnosis was 0.84 and 0.75, respectively. Conclusion: Scoring and quantification of confocal endomicroscopic images may be useful for the differential diagnosis and diagnosis of superficial invasion by squamous cell carcinoma.
-
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 7(11 Suppl) S63-7-S67 2009年11月 査読有りContrast-enhanced endoscopic ultrasonography (CE-EUS) and EUS-elastography are cutting-edge diagnostic modalities for pancreatic disorders. Each pancreatic disorder has characteristic hemodynamics. CE-EUS uses color Doppler flow imaging to classify pancreatic lesions into a spectrum of solid and cystic patterns. Although there is overlap in the patterns generated by specific types of tumors, some types of tumors tend to produce distinct flow images. EUS-elastography can assess tissue hardness by measuring its elasticity. This parameter appears to correlate with the malignant potential of the lesions. Tissue elasticity studies can provide information on both its pattern and distribution. The former is the conventional method of morphologic diagnosis, but it is restricted to observations made in a region of interest. The latter is an unbiased analysis that can be performed by image analysis software and is theoretically constant, regardless of regions of interest. The evolving modalities of CE-EUS and EUS-elastography might provide clinical utility in the diagnosis of pancreatic disorders.
-
HEPATO-GASTROENTEROLOGY 56(96) 1600-1605 2009年11月 査読有りBackgrounds/Aims: At the time of interpretation of Video Capsule Endoscopy (VCE), we sometimes see the characteristic anatomic landmarks like the major papilla of the duodenum. However, the frequency of these images and the factor affecting VCE transit are not well known. The aim of the study is to disclose the characteristics of the advance of VCE through the whole gastrointestinal tract. Methodology: We interpreted retrospectively the details of VCE with 100 patients again and analyzed the transit of VCE, significant factors affecting VCE's transit, and frequency of the anatomic landmarks observed. Results: The median esophageal transit time was 5.0 seconds; average gastric and small bowel transit times were 48.0 and 291.7 minutes. 'In-patient' and 'gastric transit time' were detected by statistical analysis as significant factors affecting VCE's transit to the cecum. The esophageal-cardiac junction, pyloric ring seen from the duodenal bulb, major papilla of the duodenum, ileo-cecal valve seen from the cecum, vermiform appendix, and anal canal were found with the following rates: 17, 33, 18, 20, 3, and 2 %. Conclusions: Present VCE has the limitations. This study may be the preliminary results for VCE investigating the whole gastrointestinal tract in the near future.
-
DIGESTIVE AND LIVER DISEASE 41(10) 735-739 2009年10月 査読有りBackground and aims: Although cyclosporin A has been reported tube effective in the treatment of severe ulcerative colitis, factors predicting its therapeutic efficacy remain unclear. Technical progress in endoscopic ultrasonography has improved visualisation of the structure of the colon wall. Here, to assess the value of endoscopic ultrasonography in predicting the response to cyclosporin A treatment, we evaluated the therapeutic effect of cyclosporin A by determining the pre- and post-cyclosporin A thickness of the mucosal layer in the rectum using endoscopic ultrasonography with an ultrasonic catheter probe. Patients and methods: Fifteen ulcerative colitis patients who did not respond to high-closes of corticosteroids were treated with cyclosporin A by continuous intravenous infusion at 4 mg/kg/day for 20 days. Before and 20 days after cyclosporin A therapy, clinical disease activity was assessed using clinical activity index scores. Colonoscopy and endoscopic ultrasonography were undertaken before and 20 clays after cyclosporin A therapy. Results: Following treatment with cyclosporin A, nine patients showed a decrease in clinical activity index score by six points or more and were defined as responders, while the other six were defined as non-responders. Endoscopic ultrasonography measurement using an ultrasonic catheter probe showed that thickness of the rectal mucosal layer before cyclosporin A was significantly greater in responders than in non-responders (p < 0.05). Further, thickness after cyclosporin A was statistically decreased (p < 0.01) in the responders but not in the non-responders. Conclusions: The ultrasonic catheter probe may represent a useful means of predicting and evaluating the efficacy of cyclosporin A treatment in severely ill ulcerative colitis patients. (C) 2009 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
-
Gastroenterology 137(4) 1223, 538-+ 2009年10月 査読有り
-
Gastroenterological Endoscopy 51(Suppl.2) 2063-2063 2009年9月
-
Gastroenterological Endoscopy 51(Suppl.2) 2094-2094 2009年9月
書籍等出版物
46講演・口頭発表等
430-
JDDW2024 第108回日本消化器内視鏡学会 2024年11月1日
-
第62回日本小腸学会学術集会 2024年10月19日
担当経験のある科目(授業)
7所属学協会
12共同研究・競争的資金等の研究課題
31-
日本学術振興会 科学研究費助成事業 2022年4月 - 2025年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(C) 2022年4月 - 2025年3月
-
厚生労働省 先進医療B 2021年2月 - 2024年6月
-
国立研究開発法人日本医療研究開発機構（AMED) 令和6年度 医療機器等研究成果展開事業（開発実践タイプ） 2024年6月
-
国立研究開発法人日本医療研究開発機構（AMED) 令和３年度難治性疾患実用化研究事業 2021年5月 - 2024年3月